{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.705, "earningsTimestamp": 1683630001, "earningsTimestampStart": 1691411400, "earningsTimestampEnd": 1691757000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.17, "epsForward": -2.45, "epsCurrentYear": -1.17, "priceEpsCurrentYear": -0.6025641, "sharesOutstanding": 111696000, "bookValue": 0.545, "fiftyDayAverage": 0.818258, "fiftyDayAverageChange": -0.113258004, "fiftyDayAverageChangePercent": -0.13841356, "twoHundredDayAverage": 1.20994, "twoHundredDayAverageChange": -0.50494, "twoHundredDayAverageChangePercent": -0.41732648, "marketCap": 78745680, "forwardPE": -0.2877551, "priceToBook": 1.2935779, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.8 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1554098400000, "priceHint": 4, "marketState": "REGULAR", "exchange": "FRA", "shortName": "PRECISION BIOSCIENCES DL", "longName": "Precision BioSciences, Inc.", "messageBoardId": "finmb_41018856", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChange": 0.0, "regularMarketTime": 1683899564, "regularMarketDayHigh": 0.705, "regularMarketDayRange": "0.685 - 0.705", "regularMarketDayLow": 0.685, "regularMarketVolume": 550, "regularMarketPreviousClose": 0.705, "bid": 0.7, "ask": 0.715, "bidSize": 0, "askSize": 0, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 0.685, "averageDailyVolume3Month": 110, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.061399996, "fiftyTwoWeekLowChangePercent": 0.09540087, "fiftyTwoWeekRange": "0.6436 - 2.001", "fiftyTwoWeekHighChange": -1.296, "fiftyTwoWeekHighChangePercent": -0.64767617, "fiftyTwoWeekLow": 0.6436, "fiftyTwoWeekHigh": 2.001, "symbol": "PBS.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "302 East Pettigrew Street", "address2": "Suite A-100", "city": "Durham", "state": "NC", "zip": "27701", "country": "United States", "phone": "919 314 5512", "fax": "480 393 5553", "website": "https://www.precisionbiosciences.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.", "fullTimeEmployees": 198, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael  Amoroso", "age": 44, "title": "Pres, CEO & Director", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": {"raw": 979041, "fmt": "979.04k", "longFmt": "979,041"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. John Alexander Kelly R.Ph.", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 623576, "fmt": "623.58k", "longFmt": "623,576"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Dario  Scimeca", "age": 46, "title": "Gen. Counsel & Sec.", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 576432, "fmt": "576.43k", "longFmt": "576,432"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Derek  Jantz Ph.D.", "age": 46, "title": "Co-Founder & Chief Science Advisor", "yearBorn": 1976, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jefferson J. Smith Ph.D.", "age": 49, "title": "Co-Founder & Chief Research Officer", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Shane  Barton", "age": 51, "title": "VP, Corp. Controller & Principal Accounting Officer", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mei  Burris", "title": "Director of Investor Relations & Fin.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Bruce  Stevens", "title": "VP of Quality & Compliance", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Maurissa  Messier", "title": "Sr. Director of Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Juli  Blanche", "title": "Chief People Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 2, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 6, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}